A Phase I, Open-Label, Two-Period, One-Sequence, Crossover Study in Healthy Subjects to Evaluate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein (Digoxin) and Breast Cancer Resistance Protein (Rosuvastatin)
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Divarasib (Primary) ; Digoxin; Rosuvastatin
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.
- 12 Nov 2024 New trial record